Your browser doesn't support javascript.
Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster.
Peng, Pai; Feng, Chengqian; Hu, Jie; He, Changlong; Deng, Haijun; Fan, Qinghong; Xiang, Jin; Tang, Guofang; Jiang, Meng-Ling; Hu, Fengyu; Li, Feng; Wang, Kai; Tang, Ni; Tang, Xiao-Ping; Huang, Ailong.
  • Peng P; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Yixue Yuan Road No.1, Chongqing 400016, China.
  • Feng C; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Hu J; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Yixue Yuan Road No.1, Chongqing 400016, China.
  • He C; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Yixue Yuan Road No.1, Chongqing 400016, China.
  • Deng H; Department of Laboratory Medicine, People's Hospital of Jiulongpo District, Chongqing, China.
  • Fan Q; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Yixue Yuan Road No.1, Chongqing 400016, China.
  • Xiang J; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Tang G; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Yixue Yuan Road No.1, Chongqing 400016, China.
  • Jiang ML; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Hu F; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Li F; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Wang K; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Tang N; Guangzhou Laboratory, Guangzhou, China.
  • Tang XP; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Yixue Yuan Road No.1, Chongqing 400016, China.
  • Huang A; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Yixue Yuan Road No.1, Chongqing 400016, China.
iScience ; 25(11): 105465, 2022 Nov 18.
Article in English | MEDLINE | ID: covidwho-2179833
ABSTRACT
To overcome the increased risk of SARS-CoV-2 reinfection or post-vaccination infection caused by the Omicron variant, Omicron-specific vaccines were considered a potential strategy. We reported the increased magnitude and breadth of antibody response against VOCs elicited by post-vaccination Delta and Omicron infection, compared to WT infection without vaccination. Then, in mouse models, three doses of Omicron-RBD immunization elicited comparable neutralizing antibody (NAb) titers with three doses of WT-RBD immunization, but the neutralizing activity was not cross-active. By contrast, a heterologous Omicron-RBD booster following two doses of WT-RBD immunization increased the NAb titers against Omicron by 9-folds than the homologous WT-RBD booster. Moreover, it retains neutralization against both WT and current VOCs. Results suggest that Omicron-specific subunit booster shows its advantages in the immune protection from both WT and current VOCs and that SARS-CoV-2 vaccines including two or more virus lineages might improve the NAb response.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.105465

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.105465